KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Shares Outstanding (Diluted Average) (2020 - 2025)

Resmed (RMD) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $146.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) fell 0.57% year-over-year to $146.6 million, compared with a TTM value of $146.6 million through Dec 2025, down 0.57%, and an annual FY2025 reading of $147.3 million, changed 0.14% over the prior year.
  • Shares Outstanding (Diluted Average) was $146.6 million for Q4 2025 at Resmed, roughly flat from $146.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $147.6 million in Q3 2024 and bottomed at $146.4 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $147.2 million, with a median of $147.3 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 0.55% in 2021, then fell 0.57% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $147.0 million in 2021, then grew by 0.22% to $147.4 million in 2022, then rose by 0.14% to $147.6 million in 2023, then dropped by 0.06% to $147.5 million in 2024, then fell by 0.57% to $146.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for RMD at $146.6 million in Q4 2025, $146.9 million in Q3 2025, and $147.3 million in Q2 2025.